Pharmaceutical Pellet Hardness Tester for Multiparticulates with 21 CFR Part 11 Audit Trail
Pharmaceutical pellets — the small (0.5–2 mm) drug-loaded multiparticulates filled into capsules or compressed into MUPS (Multiple Unit Pellet System) tablets — are the foundation of modified-release oral dosage forms. Pellets that are too soft fragment during the coating process or capsule fill, releasing drug prematurely. Pellets that are too hard resist the controlled erosion that drives the modified-release profile. Pellet hardness QC is therefore part of the GMP release specification for the API-loaded pellet, and modern pharma QC labs run this test under 21 CFR Part 11 audit-trail requirements.
Quick Answer
A pharmaceutical pellet hardness tester measures the compressive force a single pellet withstands before fracture, used in GMP QC of API-loaded multiparticulates and MUPS dosage forms. The KHT instrument supports a single-pellet method analogous to ASTM D4179 with a 0–50 N load-cell range, sub-mN resolution for pharma-pellet sizes, and 21 CFR Part 11 audit-trail logging including electronic signatures, role-based access and tamper-evident force-curve hashing. Note: pharmaceutical *tablet* hardness is a different test (USP <1217>) — this page covers pellet/multiparticulate hardness only.
Pellet Hardness vs Tablet Hardness — Two Different Tests
Before describing the pellet test it is essential to clarify what this page is *not* about. Pharmaceutical *tablet* hardness — the breaking force of a finished oral solid dose tablet — is governed by USP <1217> Tablet Breaking Force. Tablet testing uses a dedicated instrument with horizontal jaws and a 1 mm/sec constant-speed compression. KHT does not currently offer a USP <1217> tablet tester; the dominant suppliers in that segment are Erweka, Sotax, Bareiss and Pharma Test. This page covers pharmaceutical *pellet* hardness — the compressive crush strength of small (0.5–2 mm) drug-loaded multiparticulate beads filled into capsules (e.g., for proton-pump inhibitors and beta-blockers) or compressed into MUPS tablets. The pellet test is methodologically closer to ASTM D4179 single-pellet crush strength, scaled down for the smaller bead size, with sub-mN load-cell resolution and pharma-grade audit trails.
Why Pharma Pellet Hardness Decides Dissolution and Capsule Quality
API-loaded pharmaceutical pellets undergo three mechanical stresses during processing. First, fluid-bed coating — pellets are fluidized at high air velocity for 60–180 minutes while polymer coats are sprayed on; weak pellets fragment, expose uncoated cores and produce off-spec dissolution profiles. Second, capsule fill — pellets flow through dosators that compress and meter them into hard-gelatin or HPMC capsule shells; weak pellets generate fines that adhere to dosator parts and cause weight variability. Third, MUPS tableting — pellets are compressed into a tablet matrix at 5–15 kN; pellets must crush partially without fragmenting fully, a balance that is uniquely sensitive to incoming pellet hardness. Pellet hardness specs vary widely by formulation. A typical immediate-release uncoated pellet might spec 1–5 N mean crush strength; a coated controlled-release pellet 3–12 N; a hard-coated MUPS feed pellet 8–25 N. The spec is set by the formulation development team based on dissolution and capsule-fill testing, and the QC method uses pellet hardness as the routine control point.
GMP QC Method — Single-Pellet Crush Analogous to ASTM D4179
Pharmaceutical pellet hardness QC follows a single-pellet parallel-platen compression method analogous to ASTM D4179. The KHT instrument is configured with a 0–50 N high-resolution load cell (sub-mN resolution at the low end), a precision pellet-positioning fixture for the 0.5–2 mm pharma-pellet size range, and a controlled crosshead speed of 1–10 mm/min. A typical batch tests 25–50 pellets per lot, with mean, standard deviation, lower-5th-percentile and CV reported to the QC system. The method is documented in the pharmaceutical formulator's analytical procedure (typically an IH-AP or USP equivalent internal standard) referencing ASTM D4179 as the underlying test geometry. Because no USP chapter or pharmacopoeia specifies the pellet hardness method directly, each pharmaceutical company writes its own validated procedure — and the KHT validation package (IQ/OQ/PQ documentation) is designed to support this internal validation work.
21 CFR Part 11 Compliance — Audit Trail, Electronic Signatures, Data Integrity
Pharmaceutical QC labs operating under 21 CFR Part 11 must demonstrate that electronic records are trustworthy, complete, and tamper-evident. The KHT software for pharmaceutical pellet hardness includes the building blocks for 21 CFR Part 11 compliance: **Audit trail** — every test event (operator login, method selection, sample identification, force-curve acquisition, result review, report sign-off) is logged with timestamp, operator ID, and an unbroken record of any modifications. The audit log is read-only to operators and write-protected from the database side. **Electronic signatures** — supervisors review and sign off on test reports using their unique credentials; signatures are bound to the specific record and cannot be transferred or replayed. **Role-based access** — operators, reviewers, supervisors and QA each have separate permission sets; no operator can self-review their own results. **Force-curve hashing** — the raw force-displacement curve is hashed with SHA-256 at acquisition and stored alongside the result; any subsequent modification of the underlying data invalidates the hash and is flagged in the audit trail. Final 21 CFR Part 11 compliance always depends on the customer's own validation framework, SOPs and qualification work — KHT provides the IQ/OQ/PQ documentation kit to support this validation.
Where Pharmaceutical Pellet Hardness Testing Matters Most
Pellet hardness QC is most critical at three points in the pharma supply chain. First, at the API-pelletizing or extruder/spheronizer plant — every batch of inert or active multiparticulate is hardness-tested before release to the next process step. Second, at the formulation development lab — pellet hardness is one of the first responses tracked during process scale-up from lab to pilot to commercial scale. Third, at incoming-lot QC at the capsule-fill or MUPS-tableting plant — confirms that the supplier's released pellet meets the receiving plant's spec before processing. A Pharma Plant in Northern Europe used the KHT instrument for incoming-lot QC of a coated proton-pump-inhibitor pellet. The plant tracked weekly mean hardness against the supplier's COA and detected a 3-week drift in the supplier's pelletizer that the supplier's own QC had missed; the early warning triggered a process review at the supplier and prevented the drift from causing downstream dissolution failures.
Choosing the Right Pharmaceutical Pellet Hardness Tester
For pharmaceutical pellet QC, the recommended configuration is a 0–50 N high-resolution load cell with sub-mN sensitivity at the low end of the range, a 25-position rotary auto-feeder sized for 0.5–2 mm pharma pellets, parallel platens flat to ≤2 µm (tighter than the catalyst-industry standard), and the KHT software 21 CFR Part 11 module with audit trail, electronic signatures and role-based access. The instrument should ship with full IQ/OQ/PQ documentation to support customer validation under FDA, EMA and PMDA inspection.
Frequently Asked Questions
Need a Pharmaceutical Pellet Hardness Tester?
Ph. Eur. 2.9.8 and USP <1217> compliant hardness testing with 21 CFR Part 11 audit trail — tell us your tablet or multiparticulate application and we respond within 24 hours.